205 related articles for article (PubMed ID: 21895539)
1. AE37: a novel T-cell-eliciting vaccine for breast cancer.
Sears AK; Perez SA; Clifton GT; Benavides LC; Gates JD; Clive KS; Holmes JP; Shumway NM; Van Echo DC; Carmichael MG; Ponniah S; Baxevanis CN; Mittendorf EA; Papamichail M; Peoples GE
Expert Opin Biol Ther; 2011 Nov; 11(11):1543-50. PubMed ID: 21895539
[TBL] [Abstract][Full Text] [Related]
2. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
[TBL] [Abstract][Full Text] [Related]
3. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
[TBL] [Abstract][Full Text] [Related]
4. Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide.
Gates JD; Clifton GT; Benavides LC; Sears AK; Carmichael MG; Hueman MT; Holmes JP; Jama YH; Mursal M; Zacharia A; Ciano K; Khoo S; Stojadinovic A; Ponniah S; Peoples GE
Vaccine; 2010 Nov; 28(47):7476-82. PubMed ID: 20858449
[TBL] [Abstract][Full Text] [Related]
5. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
6. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M; Kallinteris NL; von Hofe E
Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
[TBL] [Abstract][Full Text] [Related]
7. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.
Czerniecki BJ; Koski GK; Koldovsky U; Xu S; Cohen PA; Mick R; Nisenbaum H; Pasha T; Xu M; Fox KR; Weinstein S; Orel SG; Vonderheide R; Coukos G; DeMichele A; Araujo L; Spitz FR; Rosen M; Levine BL; June C; Zhang PJ
Cancer Res; 2007 Feb; 67(4):1842-52. PubMed ID: 17293384
[TBL] [Abstract][Full Text] [Related]
8. CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37).
Mittendorf EA; Holmes JP; Murray JL; von Hofe E; Peoples GE
Expert Opin Biol Ther; 2009 Jan; 9(1):71-8. PubMed ID: 19063694
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu as a target for cancer vaccines.
Baxevanis CN; Voutsas IF; Gritzapis AD; Perez SA; Papamichail M
Immunotherapy; 2010 Mar; 2(2):213-26. PubMed ID: 20635929
[TBL] [Abstract][Full Text] [Related]
10. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.
Wiedermann U; Davis AB; Zielinski CC
Breast Cancer Res Treat; 2013 Feb; 138(1):1-12. PubMed ID: 23340862
[TBL] [Abstract][Full Text] [Related]
11. Positive Phase II interim data on AE37 cancer vaccine released.
Hum Vaccin Immunother; 2012 Feb; 8(2):152. PubMed ID: 22426363
[No Abstract] [Full Text] [Related]
12. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Holmes JP; Clifton GT; Patil R; Benavides LC; Gates JD; Stojadinovic A; Mittendorf EA; Ponniah S; Peoples GE
Cancer; 2011 Feb; 117(3):463-71. PubMed ID: 20845479
[TBL] [Abstract][Full Text] [Related]
13. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
[TBL] [Abstract][Full Text] [Related]
14. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
[TBL] [Abstract][Full Text] [Related]
15. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.
Disis ML; Schiffman K; Guthrie K; Salazar LG; Knutson KL; Goodell V; dela Rosa C; Cheever MA
J Clin Oncol; 2004 May; 22(10):1916-25. PubMed ID: 15143085
[TBL] [Abstract][Full Text] [Related]
16. Immunizing against breast cancer: a new swing for an old sword.
Curigliano G; Locatelli M; Fumagalli L; Goldhirsch A
Breast; 2009 Oct; 18 Suppl 3():S51-4. PubMed ID: 19914543
[TBL] [Abstract][Full Text] [Related]
17. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.
Benavides LC; Sears AK; Gates JD; Clifton GT; Clive KS; Carmichael MG; Holmes JP; Mittendorf EA; Ponniah S; Peoples GE
Expert Rev Vaccines; 2011 Feb; 10(2):201-10. PubMed ID: 21332269
[TBL] [Abstract][Full Text] [Related]
18. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Knutson KL; Schiffman K; Cheever MA; Disis ML
Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
[TBL] [Abstract][Full Text] [Related]
19. Vaccine immunotherapy in breast cancer treatment: promising, but still early.
Curigliano G; Spitaleri G; Dettori M; Locatelli M; Scarano E; Goldhirsch A
Expert Rev Anticancer Ther; 2007 Sep; 7(9):1225-41. PubMed ID: 17892423
[TBL] [Abstract][Full Text] [Related]
20. AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence.
McCarthy PM; Clifton GT; Vreeland TJ; Adams AM; O'Shea AE; Peoples GE
Expert Opin Investig Drugs; 2021 Jan; 30(1):5-11. PubMed ID: 33191799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
